MET signalling: principles and functions in development, organ regeneration and cancer
The MET tyrosine kinase receptor (also known as the HGF receptor) promotes tissue
remodelling, which underlies developmental morphogenesis, wound repair, organ …
remodelling, which underlies developmental morphogenesis, wound repair, organ …
Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils
D Torti, L Trusolino - EMBO molecular medicine, 2011 - embopress.org
A decade has elapsed since the concept of oncogene addiction was first proposed. It
postulates that–despite the diverse array of genetic lesions typical of cancer–some tumours …
postulates that–despite the diverse array of genetic lesions typical of cancer–some tumours …
MET is required for the recruitment of anti-tumoural neutrophils
Mutations or amplification of the MET proto-oncogene are involved in the pathogenesis of
several tumours,,,, which rely on the constitutive engagement of this pathway for their growth …
several tumours,,,, which rely on the constitutive engagement of this pathway for their growth …
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal …
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from
therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the …
therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the …
Epidermal growth factor receptor in glioblastoma
H Xu, H Zong, C Ma, X Ming, M Shang… - Oncology …, 2017 - spandidos-publications.com
Mutations in the epidermal growth factor receptor (EGFR) are commonly occurring in
glioblastoma. Enhanced activation of EGFR can occur through a variety of different …
glioblastoma. Enhanced activation of EGFR can occur through a variety of different …
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
G Migliardi, F Sassi, D Torti, F Galimi, ER Zanella… - Clinical Cancer …, 2012 - AACR
Purpose: Gene mutations along the Ras pathway (KRAS, NRAS, BRAF, PIK3CA) occur in
approximately 50% of colorectal cancers (CRC) and correlate with poor response to anti …
approximately 50% of colorectal cancers (CRC) and correlate with poor response to anti …
Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions
Plexin transmembrane receptors and their semaphorin ligands, as well as their co-receptors
(Neuropilin, Integrin, VEGFR2, ErbB2, and Met kinase) are emerging as key regulatory …
(Neuropilin, Integrin, VEGFR2, ErbB2, and Met kinase) are emerging as key regulatory …
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib—a phase II trial
ME Hegi, AC Diserens, P Bady, Y Kamoshima… - Molecular cancer …, 2011 - AACR
Amplification of the epidermal growth factor receptor (EGFR) gene is one of the most
common oncogenic alterations in glioblastoma (45%) making it a prime target for therapy …
common oncogenic alterations in glioblastoma (45%) making it a prime target for therapy …
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET
C Basilico, S Pennacchietti, E Vigna, C Chiriaco… - Clinical Cancer …, 2013 - AACR
Purpose: MET, the high-affinity receptor for hepatocyte growth factor, is frequently
deregulated in human cancer. Tivantinib (ARQ197; Arqule), a staurosporine derivative that …
deregulated in human cancer. Tivantinib (ARQ197; Arqule), a staurosporine derivative that …
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
The establishment of the role of MET in human cancer has led to the development of small-
molecule inhibitors, many of which are currently in clinical trials. Thus far, nothing is known …
molecule inhibitors, many of which are currently in clinical trials. Thus far, nothing is known …